tradingkey.logo
tradingkey.logo
Search

Ocular Therapeutix Inc

OCUL
Add to Watchlist
9.470USD
-0.350-3.56%
Close 07/01, 16:00ETQuotes delayed by 15 min
2.07BMarket Cap
LossP/E TTM

TradingKey Stock Score of Ocular Therapeutix Inc

Currency: USD Updated: 2026-07-01

Key Insights

Ocular Therapeutix Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 57 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.73.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ocular Therapeutix Inc's Score

Industry at a Glance

Industry Ranking
57 / 157
Overall Ranking
143 / 4564
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Ocular Therapeutix Inc Highlights

StrengthsRisks
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Growing
The company is in a growing phase, with the latest annual income totaling USD 51.95M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 51.95M.
Fairly Valued
The company’s latest PE is -6.59, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 212.47M shares, increasing 5.74% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.49M shares of this stock.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
26.727
Target Price
+172.17%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Ocular Therapeutix Inc?

The TradingKey Stock Score provides a comprehensive assessment of Ocular Therapeutix Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Ocular Therapeutix Inc’s performance and outlook.

How do we generate the financial health score of Ocular Therapeutix Inc?

To generate the financial health score of Ocular Therapeutix Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Ocular Therapeutix Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Ocular Therapeutix Inc.

How do we generate the company valuation score of Ocular Therapeutix Inc?

To generate the company valuation score of Ocular Therapeutix Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Ocular Therapeutix Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Ocular Therapeutix Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Ocular Therapeutix Inc.

How do we generate the earnings forecast score of Ocular Therapeutix Inc?

To calculate the earnings forecast score of Ocular Therapeutix Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Ocular Therapeutix Inc’s future.

How do we generate the price momentum score of Ocular Therapeutix Inc?

When generating the price momentum score for Ocular Therapeutix Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Ocular Therapeutix Inc’s prices. A higher score indicates a more stable short-term price trend for Ocular Therapeutix Inc.

How do we generate the institutional confidence score of Ocular Therapeutix Inc?

To generate the institutional confidence score of Ocular Therapeutix Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Ocular Therapeutix Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Ocular Therapeutix Inc.

How do we generate the risk management score of Ocular Therapeutix Inc?

To assess the risk management score of Ocular Therapeutix Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Ocular Therapeutix Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Ocular Therapeutix Inc.